Omeros | OMER - Operating Profit


Omeros reported $-35.41M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Adma Biologics USD 62.75M 11.74M Dec/2025
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 4.62M 1.43M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Rockwell Medical USD 515K 1.84M Jun/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026
Xoma USD -15.64M 5.56M Sep/2024